{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:02:20Z","timestamp":1788390140966,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.bcp.2023.115875","type":"journal-article","created":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T14:51:17Z","timestamp":1697899877000},"page":"115875","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Mitochondrial complex I inhibition by homoharringtonine: A novel strategy for suppression of chronic myeloid leukemia"],"prefix":"10.1016","volume":"218","author":[{"given":"Han","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengchen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fancheng","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guibin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Mingyuen Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7639-2456","authenticated-orcid":false,"given":"Guozhen","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2023.115875_b0005","doi-asserted-by":"crossref","unstructured":"M.W. Deininger, N.P. Shah, J.K. Altman, E. Berman, R. Bhatia, B. Bhatnagar, D.J. DeAngelo, J. Gotlib, G. Hobbs, L. Maness, M. Mead, L. Metheny, S. Mohan, J.O. Moore, K. Naqvi, V. Oehler, A.M. Pallera, M. Patnaik, K. Pratz, I. Pusic, M.G. Rose, B.D. Smith, D.S. Snyder, K.L. Sweet, M. Talpaz, J. Thompson, D.T. Yang, K.M. Gregory, H. Sundar, Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology, J Natl Compr Canc Netw. 18(10) (2020) 1385-1415.","DOI":"10.6004\/jnccn.2020.0047"},{"issue":"9976","key":"10.1016\/j.bcp.2023.115875_b0010","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.bcp.2023.115875_b0015","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/s41375-019-0490-0","article-title":"Chronic myeloid leukemia stem cells","volume":"33","author":"Houshmand","year":"2019","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.bcp.2023.115875_b0020","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2023.115875_b0025","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41375-022-01736-5","article-title":"Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia","volume":"37","author":"Senapati","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bcp.2023.115875_b0030","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1186\/s13287-021-02659-1","article-title":"Chronic myeloid leukemia stem cells: targeting therapeutic implications","volume":"12","author":"Mojtahedi","year":"2021","journal-title":"Stem Cell Res Ther"},{"issue":"10","key":"10.1016\/j.bcp.2023.115875_b0035","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.leukres.2010.04.016","article-title":"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review","volume":"34","author":"An","year":"2010","journal-title":"Leuk. Res."},{"issue":"4","key":"10.1016\/j.bcp.2023.115875_b0040","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.hoc.2017.04.006","article-title":"Tyrosine kinase inhibitor treatment for newly diagnosed chronic myeloid leukemia","volume":"31","author":"Radich","year":"2017","journal-title":"Hematol. Oncol. Clin. N. Am."},{"issue":"1","key":"10.1016\/j.bcp.2023.115875_b0045","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/PPO.0000000000000165","article-title":"The role of new tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"22","author":"Pophali","year":"2016","journal-title":"Cancer J."},{"issue":"5","key":"10.1016\/j.bcp.2023.115875_b0050","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc2126","article-title":"Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia","volume":"7","author":"Weisberg","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"19","key":"10.1016\/j.bcp.2023.115875_b0055","doi-asserted-by":"crossref","first-page":"10726","DOI":"10.1021\/acs.jmedchem.0c00507","article-title":"Medicinal chemistry strategies for the development of kinase inhibitors targeting point mutations","volume":"63","author":"Lu","year":"2020","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bcp.2023.115875_b0060","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1177\/1060028013501144","article-title":"Ponatinib: a new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"47","author":"Shamroe","year":"2013","journal-title":"Ann. Pharmacother."},{"issue":"18","key":"10.1016\/j.bcp.2023.115875_b0065","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21186556","article-title":"Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis","volume":"21","author":"Zeng","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.bcp.2023.115875_b0070","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2174\/1568009617666171002142659","article-title":"Ponatinib: a review of efficacy and safety","volume":"18","author":"Massaro","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"issue":"7","key":"10.1016\/j.bcp.2023.115875_b0075","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.3324\/haematol.2012.083006","article-title":"Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors","volume":"98","author":"Nicolini","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.bcp.2023.115875_b0080","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.phytol.2018.02.005","article-title":"Novel biflavonoids from Cephalotaxus oliveri Mast","volume":"24","author":"Ren","year":"2018","journal-title":"Phytochem. Lett."},{"key":"10.1016\/j.bcp.2023.115875_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2021.112770","article-title":"Caffeic acid phenethyl ester protects against doxorubicin-induced cardiotoxicity and increases chemotherapeutic efficacy by regulating the unfolded protein response","volume":"159","author":"Zhang","year":"2022","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.bcp.2023.115875_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114637","article-title":"Identification of dihydrotanshinone I as an ERp57 inhibitor with anti-breast cancer properties via the UPR pathway","volume":"190","author":"Shi","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115875_b0095","doi-asserted-by":"crossref","first-page":"e1620","DOI":"10.1038\/cddis.2014.587","article-title":"CtBP maintains cancer cell growth and metabolic homeostasis via regulating SIRT4","volume":"6","author":"Wang","year":"2015","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.bcp.2023.115875_b0100","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13020-023-00814-9","article-title":"Integrating animal experiments, mass spectrometry and network-based approach to reveal the sleep-improving effects of Ziziphi Spinosae Semen and \u03b3-aminobutyric acid mixture","volume":"18","author":"Ren","year":"2023","journal-title":"Chin. Med."},{"issue":"3","key":"10.1016\/j.bcp.2023.115875_b0105","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1021\/jm301581y","article-title":"Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib","volume":"56","author":"Ren","year":"2013","journal-title":"J. Med. Chem."},{"issue":"6516","key":"10.1016\/j.bcp.2023.115875_b0110","doi-asserted-by":"crossref","first-page":"eabc4209","DOI":"10.1126\/science.abc4209","article-title":"The coupling mechanism of mammalian respiratory complex I","volume":"370","author":"Kampjut","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bcp.2023.115875_b0115","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","article-title":"Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy","volume":"11","author":"Rossari","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115875_b0120","first-page":"113","article-title":"Homoharringtonine promotes BCR-ABL degradation through the p62-mediated autophagy pathway","volume":"43","author":"Li","year":"2020","journal-title":"Oncol. Rep."},{"issue":"23","key":"10.1016\/j.bcp.2023.115875_b0125","doi-asserted-by":"crossref","first-page":"37594","DOI":"10.18632\/oncotarget.16731","article-title":"Homoharringtonine suppresses imatinib resistance via the Bcl-6\/p53 pathway in chronic myeloid leukemia cell lines","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.bcp.2023.115875_b0130","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s12032-013-0836-9","article-title":"Homoharringtonine contributes to imatinib sensitivity by blocking the EphB4\/RhoA pathway in chronic myeloid leukemia cell lines","volume":"31","author":"Huang","year":"2014","journal-title":"Med. Oncol."},{"issue":"10","key":"10.1016\/j.bcp.2023.115875_b0135","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/nm.4399","article-title":"Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells","volume":"23","author":"Kuntz","year":"2017","journal-title":"Nat. Med."},{"issue":"19","key":"10.1016\/j.bcp.2023.115875_b0140","doi-asserted-by":"crossref","first-page":"11836","DOI":"10.3390\/ijms231911836","article-title":"B-Lymphoid blast phase-chronic myeloid leukemia: current therapeutics","volume":"23","author":"Yohannan","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.bcp.2023.115875_b0145","first-page":"2711","article-title":"The Lyn-SIRT1 signaling pathway is involved in imatinib resistance in chronic myeloid leukaemia","volume":"12","author":"Teng","year":"2020","journal-title":"Am. J. Transl. Res."},{"issue":"7","key":"10.1016\/j.bcp.2023.115875_b0150","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1172\/JCI127080","article-title":"SIRT1 regulates metabolism and leukemogenic potential in CML stem cells","volume":"129","author":"Abraham","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"22","key":"10.1016\/j.bcp.2023.115875_b0155","doi-asserted-by":"crossref","first-page":"10033","DOI":"10.1021\/jm301188x","article-title":"Design, synthesis, and biological evaluation of 3-(1H\u20131,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)\u2013>isoleucine(315) mutant","volume":"55","author":"Li","year":"2012","journal-title":"J. Med. Chem."},{"issue":"17","key":"10.1016\/j.bcp.2023.115875_b0160","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1016\/j.bmcl.2015.07.006","article-title":"Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant","volume":"25","author":"Lu","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.bcp.2023.115875_b0165","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/14756366.2016.1250757","article-title":"Synthesis and identification of GZD856 as an orally bioavailable Bcr-Abl(T315I) inhibitor overcoming acquired imatinib resistance","volume":"32","author":"Lu","year":"2017","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2023.115875_b0170","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.apsb.2020.11.009","article-title":"Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation","volume":"11","author":"Jiang","year":"2021","journal-title":"Acta Pharm Sin b. B"},{"issue":"1","key":"10.1016\/j.bcp.2023.115875_b0175","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1038\/s41467-020-19778-7","article-title":"Essential role of accessory subunit LYRM6 in the mechanism of mitochondrial complex I","volume":"11","author":"Galemou Yoga","year":"2020","journal-title":"Nat. Commun."},{"issue":"22","key":"10.1016\/j.bcp.2023.115875_b0180","doi-asserted-by":"crossref","first-page":"13880","DOI":"10.3390\/ijms232213880","article-title":"Mitochondrial Respiratory Chain Supercomplexes: From Structure to Function","volume":"23","author":"Guan","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"17","key":"10.1016\/j.bcp.2023.115875_b0190","doi-asserted-by":"crossref","first-page":"e139933","DOI":"10.1172\/JCI139933","article-title":"Petasin potently inhibits mitochondrial complex I-based metabolism that supports tumor growth and metastasis","volume":"131","author":"Heishima","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2023.115875_b0195","doi-asserted-by":"crossref","unstructured":"S. Jain, C. Hu, J. Kluza, W. Ke, G. Tian, M. Giurgiu, A. Bleilevens, A.R. Campos, A. Charbono, E. Stickeler, J. Maurer, E. Holinski-Feder, A. Vaisburg, M. Bureik, G. Luo, P. Marchetti, Y. Cheng, D.A. Wolf, Metabolic targeting of cancer by a ubiquinone uncompetitive inhibitor of mitochondrial complex I, Cell Chem Biol. 29(3) (2022) 436-450 e15.","DOI":"10.1016\/j.chembiol.2021.11.002"},{"key":"10.1016\/j.bcp.2023.115875_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106654","article-title":"Inhibition of bladder cancer growth with homoharringtonine by inactivating integrin alpha5\/beta1-FAK\/Src axis: A novel strategy for drug application","volume":"188","author":"Wu","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2023.115875_b0205","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.trsl.2022.06.017","article-title":"Identification of Homoharringtonine as a potent inhibitor of glioblastoma cell proliferation and migration","volume":"251","author":"Porc\u00f9","year":"2023","journal-title":"Transl. Res."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223004665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223004665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T01:07:38Z","timestamp":1731028058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295223004665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":40,"alternative-id":["S0006295223004665"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115875","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mitochondrial complex I inhibition by homoharringtonine: A novel strategy for suppression of chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115875","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115875"}}